Press Releases

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company’s Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway... Read More

Company Refutes Latest Feuerstein False Headline and Attacks BETHESDA, Md., June 20, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today refuted Adam Feuerstein’s latest false headline and attack on the Company, and reaffirmed the Company’s recent interim data announcements from its Phase I/II clinical trial of... Read More

BETHESDA, Md., June 16, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been added to two prestigious Russell Indexes:  the Russell Global and the Russell 3,000 Indexes.  The preliminary announcement was made on Saturday, June 14, 2014, and becomes effective on June 27, 2014. The Russell 3,000 Index... Read More

All 9 Out Of 9 Patients Who Have Reached 4 Injections Are Showing Tumor Cell Death, Tumor Shrinkage And/Or Stabilization Of Disease BETHESDA, Md., June 11, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9... Read More

First Site Opened In Late May, 7 More Sites Now Scheduled During June and July BETHESDA, Md., June 10, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.  The first site to open in Germany was a medical center in Dresden, which was initiated in lat... Read More